期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 80, 期 5, 页码 550-557出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-219174
关键词
cytokines; inflammation; chemokines; immune system diseases; therapeutics
类别
资金
- NIH/NHLBI [1R01HL146206, 3R01HL146206--02S1]
- VA ORD [iK2CX001074]
The search for effective COVID-19 management strategies is ongoing, with colchicine showing promise in targeting multiple mechanisms associated with excessive inflammation. Outpatient treatment with colchicine could potentially reduce the need for hospitalization and mortality due to COVID-19, benefiting both resource-replete and resource-poor regions by reducing the demand for rare or expensive care resources.
The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据